BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30349952)

  • 21. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma.
    Boonla C; Sripa B; Thuwajit P; Cha-On U; Puapairoj A; Miwa M; Wongkham S
    World J Gastroenterol; 2005 Aug; 11(32):4939-46. PubMed ID: 16124042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model.
    Iguchi T; Yamashita N; Aishima S; Kuroda Y; Terashi T; Sugimachi K; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
    Oncology; 2009; 76(4):293-300. PubMed ID: 19262069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
    Aishima S; Fujita N; Mano Y; Kubo Y; Tanaka Y; Taketomi A; Shirabe K; Maehara Y; Oda Y
    Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour.
    Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
    Histopathology; 2006 Jul; 49(1):35-44. PubMed ID: 16842244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
    Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
    Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma.
    Yamada M; Yamamoto Y; Sugiura T; Kakuda Y; Ashida R; Tamura S; Okamura Y; Ito T; Ohgi K; Nakanuma Y; Uesaka K
    Anticancer Res; 2019 Apr; 39(4):2121-2127. PubMed ID: 30952758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters.
    Zhai B; Yan HX; Liu SQ; Chen L; Wu MC; Wang HY
    World J Gastroenterol; 2008 Jun; 14(23):3739-44. PubMed ID: 18595142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy.
    Abe T; Amano H; Shimamoto F; Hattori M; Kuroda S; Kobayashi T; Tashiro H; Ohdan H
    Eur J Surg Oncol; 2015 Nov; 41(11):1515-21. PubMed ID: 26210654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
    Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
    Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma.
    Shinozaki A; Shibahara J; Noda N; Tanaka M; Aoki T; Kokudo N; Fukayama M
    Virchows Arch; 2011 Jul; 459(1):73-80. PubMed ID: 21607649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
    Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
    BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.
    Terashita K; Chuma M; Hatanaka Y; Hatanaka K; Mitsuhashi T; Yokoo H; Ohmura T; Ishizu H; Muraoka S; Nagasaka A; Tsuji T; Yamamoto Y; Kurauchi N; Shimoyama N; Toyoda H; Kumada T; Kaneoka Y; Maeda A; Ogawa K; Natsuizaka M; Kamachi H; Kakisaka T; Kamiyama T; Taketomi A; Matsuno Y; Sakamoto N
    J Clin Pathol; 2016 Jul; 69(7):593-9. PubMed ID: 26670746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
    Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
    Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.
    Li T; Qin LX; Zhou J; Sun HC; Qiu SJ; Ye QH; Wang L; Tang ZY; Fan J
    Liver Int; 2014 Jul; 34(6):953-60. PubMed ID: 24134199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
    Lok T; Chen L; Lin F; Wang HL
    Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.
    Sakamoto K; Imai K; Higashi T; Taki K; Nakagawa S; Okabe H; Nitta H; Hayashi H; Chikamoto A; Ishiko T; Beppu T; Baba H
    Cancer Sci; 2015 Sep; 106(9):1153-62. PubMed ID: 26132727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments.
    Tavolari S; Deserti M; Vasuri F; Curti S; Palloni A; Pinna AD; Cescon M; Frega G; De Lorenzo S; Barbera MA; Garajova I; Ricciardiello L; Malvi D; D'Errico-Grigioni A; Pantaleo MA; Brandi G
    Eur J Cancer; 2019 Jan; 106():160-170. PubMed ID: 30528800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma.
    Nakanuma Y; Harada K; Ishikawa A; Zen Y; Sasaki M
    J Hepatobiliary Pancreat Surg; 2003; 10(4):265-81. PubMed ID: 14598145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular factors associated with recurrence and survival following hepatectomy in patients with intrahepatic cholangiocarcinoma: a guide to adjuvant clinical trials.
    Schiffman SC; Nowacki MR; Spencer L; McMasters KM; Scoggins CR; Martin RC
    J Surg Oncol; 2014 Feb; 109(2):98-103. PubMed ID: 24122302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
    Morine Y; Imura S; Ikemoto T; Iwahashi S; Saito YU; Shimada M
    Anticancer Res; 2017 Oct; 37(10):5701-5705. PubMed ID: 28982889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.